156294-36-9
Chemical Structure
Larotaxel
Synonym(s): XRP9881
- CAS No.: 156294-36-9
- Formula:C45H53NO14
- Molecular Weight:831.90
IUPAC Name: (1S,2S,4R,7R,8aR,9aS,10aR,12aS,12bR)-1-(benzoyloxy)-4-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-2-hydroxy-5,13,13-trimethyl-8-oxo-1,3,4,7,8,9,9a,10,10a,12b-decahydro-2H-2,6-methanocyclodeca[3,4]cyclopropa[4,5]benzo[1,2-b]oxete-7,12a(12H)-diyl diacetate
InChIKey: DXOJIXGRFSHVKA-DHQLGJJCSA-N
SMILES: O=C([C@]1([H])OC(C)=O)[C@@]23[C@@]([C@@H]([C@@]4(O)C(C)(C)C1=C([C@H](OC([C@H](O)[C@H](C5=CC=CC=C5)NC(OC(C)(C)C)=O)=O)C4)C)OC(C6=CC=CC=C6)=O)([H])[C@]7([C@@](OC7)([H])C[C@@H]2C3)OC(C)=O
Biological Activity: Larotaxel (XRP9881) is an orally active and blood-brain barrier penetrant Microtubule stabilizer with an IC50 of 0.21 μM. Larotaxel shows activity in Taxane-resistant tumor models. Larotaxel exhibits antitumor activity in intracranial glioblastoma models. Larotaxel can be used for research on advanced solid tumors[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Larotaxel | 99.50% | Larotaxel (XRP9881) is an orally active and blood-brain barrier penetrant Microtubule stabilizer with an IC50 of 0.21 μM. Larotaxel shows activity in Taxane-resistant tumor models. Larotaxel exhibits antitumor activity in intracranial glioblastoma models. Larotaxel can be used for research on advanced solid tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Larotaxel-d9 | Larotaxel-d9 (XRP9881-d9) is the d9-labeled Larotaxel (HY-125374). Larotaxel (XRP9881) is an orally active and blood-brain barrier penetrant Microtubule stabilizer with an IC50 of 0.21 μM. Larotaxel shows activity in Taxane-resistant tumor models. Larotaxel exhibits antitumor activity in intracranial glioblastoma models. Larotaxel can be used for research on advanced solid tumors. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yamamoto N, et al. Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours. Cancer chemotherapy and pharmacology. 2009 Dec;65(1):129-36.
- [2]. Men L, et al. Metabolism of TM-2, a potential antitumor drug, in rats by using LC-MS. Journal of separation science. 2014 Mar;37(6):625-9.
